FREDERICK, Md. – A wearable by BioElectronics that manages chronic pain has been approved by the U.K.’s National Health Service and can now be prescribed by physicians there. The government-funded public health service has also agreed to reimbursement for the mHealth device, as well. “This is a major win for pain sufferers in the U.K., since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” said Ian Rawe, director of clinical research at BioElectronics, in a statement. “We commend this move by the NHS, as this will open up the doors for reimbursement in the U.S. and other managed care markets.” The ActiPatch regulates peripheral nerve activity to provide pain relief. It was approved by the NHS based on clinical evidence and a health economics study, which found that the wearable significantly decreased pain and improved quality of life, while reducing overall health care costs by 42%. “This will likely have a tremendous impact on our sales and marketability of the product in the U.K. and elsewhere,” said Keith Nalepka, vice president of sales and marketing at BioElectronics, in a statement.
You are here: / / NHS approves wearable for chronic pain management